Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
Adverum Biotechnologies(ADVM) Newsfilter·2024-03-19 04:05- Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD - - Completed $127.5 million private placement financing with new and existing institutional investors - - Cash runway expected into late 2025 – - 1-for-10 reverse stock split to be effective March 21, 2024 - REDWOOD CITY, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-st ...